May 1, 2018 08:01 AM EDT

Biogen tosses in an extra $50M for a bigger slice of the royalties for its PhIII Alzheimer’s drug aducanumab

John Carroll

Editor & Founder

Biogen $BIIB is once again signaling its confidence in the late-stage success of its high-risk Alzheimer’s drug aducanumab this morning, handing out $50 million …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen tosses in an extra $50M for a bigger slice of the royalties for its PhIII Alzheimer’s drug aducanumab

John Carroll

Editor & Founder

Sign up to read this article for free.

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Agenus launches biologics manufacturing business to generate cash

Bio­gen toss­es in an ex­tra $50M for a big­ger slice of the roy­al­ties for its PhI­II Alzheimer’s drug ad­u­canum­ab

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

FDA de­fends in­creased use of guid­ance in new re­port to Con­gress

Sanofi ear­marks €1B for new in­sulin pro­duc­tion fac­to­ry in Bei­jing

Agenus launch­es bi­o­log­ics man­u­fac­tur­ing busi­ness to gen­er­ate cash

Biogen tosses in an extra $50M for a bigger slice of the royalties for its PhIII Alzheimer’s drug aducanumab

Scott Gottlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this country’

Novartis pays $1B upfront for PTC's Phase 2 Huntington's drug

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

FDA defends increased use of guidance in new report to Congress

Sanofi earmarks €1B for new insulin production factory in Beijing

Agenus launches biologics manufacturing business to generate cash